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Background: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate
cancer (PC) expression has theranostic utility.
Objective: To elucidate PC PSMA expression and associate this with defective DNA
damage repair (DDR).
Design, setting, and participants: Membranous PSMA (mPSMA) expression was scored
immunohistochemically from metastatic castration-resistant PC (mCRPC) and match-
ing, same-patient, diagnostic biopsies, and correlated with next-generation sequencing
(NGS) and clinical outcome data.
Outcomemeasurements and statistical analysis: Expression of mPSMAwas quantitated
by modified H-score. Patient DNA was tested by NGS. Gene expression and activity
scores were determined from mCRPC transcriptomes. Statistical correlations utilised
Wilcoxon signed rank tests, survival was estimated by Kaplan-Meier test, and sample
heterogeneity was quantified by Shannon's diversity index.
Results and limitations: Expression of mPSMA at diagnosis was associated with higher
Gleason grade (p = 0.04) and worse overall survival (p = 0.006). Overall, mPSMA expres-
sion levels increased at mCRPC (median H-score [interquartile range]: castration-
sensitive prostate cancer [CSPC] 17.5 [0.0–60.0] vs mCRPC 55.0 [2.8–117.5]). Surprisingly,
42% (n = 16) of CSPC and 27% (n = 16) of mCRPC tissues sampled had no detectable
mPSMA (H-score <10). Marked intratumour heterogeneity of mPSMA expression, with
foci containing no detectable PSMA, was observed in all mPSMA expressing CSPC (100%)
and 37 (84%) mCRPC biopsies. Heterogeneous intrapatient mPSMA expression between
metastases was also observed, with the lowest expression in liver metastases. Tumours
with DDR had higher mPSMA expression (p = 0.016; 87.5 [25.0–247.5] vs 20 [0.3–98.8];
difference in medians 60 [5.0–95.0]); validation cohort studies confirmed higher
mPSMAexpression in patientswith deleterious aberrations in BRCA2 (p < 0.001;median
H-score: 300 [165–300]; difference inmedians 195.0 [100.0–270.0]) and ATM (p = 0.005;
212.5 [136.3–300]; difference in medians 140.0 [55.0–200]) than in molecularly unse-* Corresponding author. Division of Clinical Studies, The Institute of Cancer Research, Downs Road,
Sutton, Surrey SM2 5PT, UK. Tel. +44 02087224028; Fax: +44 02086427979.
de-Bono@icr.ac.uk (J.S. de Bono).E-mail address: johann.https://doi.org/10.1016/j.eururo.2019.06.030
0302-2838/© 2019 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncopean Association of Urology. This is an open access article
-nd/4.0/).
lected mCRPC biopsies (55.0 [2.75–117.5]). Validation studies using mCRPC transcrip-
tomes corroborated these findings, also indicating that SOX2 high tumours have low
PSMA expression.
Conclusions: Membranous PSMA expression is upregulated in some but not all PCs,
with mPSMA expression demonstratingmarked inter- and intrapatient heterogeneity.
DDR aberrations are associated with higher mPSMA expression and merit further
evaluation as predictive biomarkers of response for PSMA-targeted therapies in larger,
prospective cohorts.
Patient summary: Through analysis of prostate cancer samples, we report that the
presence of prostate-specific membrane antigen (PSMA) is extremely variable both
within one patient and between different patients. This may limit the usefulness of
PSMA scans and PSMA-targeted therapies. We show for the first time that prostate
cancers with defective DNA repair produce more PSMA and so may respond better to
PSMA-targeting treatments.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://crea-
tivecommons.org/licenses/by-nc-nd/4.0/).
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Prostate-specific membrane antigen (PSMA) is a type II
transmembrane protein with enzymatic function as a folate
hydrolase-carboxypeptidase [1]. PSMA is predominantly
localised to five sites: the prostate, the kidney, salivary
glands, nervous system glia, and the small bowel jejunal
brush border. In astrocytes and Schwann cells, PSMA has
been shown to modulate signal transduction pathways by
hydrolysing the neurotransmitter N-acetyl aspartylgluta-
mate (NAAG). At the jejunal brush border, PSMA assists in
folate absorption by removing the C-terminal glutamates
from dietary folates. The role of PSMA in the prostate is less
clear, although it has been implicated in folate and
glutamate cellular uptake, which are key to DNA synthesis
and repair, amino acid and polyamine generation, and PI3K-
Akt signalling [1–3].
Nevertheless, PSMA is widely recognised to be over-
expressed in prostate cancer (PC) [4,5], emerging as a
promising target for theranostics. However, concerns
remain regarding this strategy. For example, although
multiple positron-emission tomography/computed to-
mography (PET/CT) studies indicate the superiority of
PSMA-PET over choline PET [6], the reported sensitivity of
these diagnostic techniques encompasses a broad range
[7]. Similarly, while radiolabelled anti-PSMA therapies
such as 177Lu-PSMA-617 appear well tolerated and result in
prostate-specific antigen (PSA) level decreases of 50% in
30–60% of metastatic castration-resistant prostate cancer
(mCRPC) patients [8,9], nonresponder rates of approxi-
mately 30% have been reported [9–11], with antitumour
activity being higher when PSMA-PET based patient
selection is pursued.
One potential explanation for these discrepancies is
heterogeneity of PSMA expression [12]. However, the extent
of, implications of, and mechanisms underlying this
phenomenon remain poorly understood due, in part, to
previous studies investigating PSMA expression commonly
using antibodies, such as the 7E11 anti-PSMA monoclonal
antibody, that recognise the intracellular portion of PSMA
[4,5,13]. As such, these antibodies are susceptible to
overestimating PSMA expression, given that they recognisecytoplasmic PSMA, which is not clinically actionable, as
evidenced by early clinical trials of radioimmunoconjugates
using these antibodies that showed poor antitumour
activity [14,15]. Subsequently, new antibodies that recog-
nise the extracellular portion of PSMA have been developed
[16], allowing more accurate assessment of PSMA expres-
sion. However, despite this, more recent publications have
been limited by a lack of differentiation between cyto-
plasmic PSMA expression and more clinically relevant
membranous PSMA (mPSMA) [17,18]. We therefore elected
to evaluate, by immunohistochemistry (IHC), the variability
of mPSMA protein expression in mCRPC biopsies and, when
available, the matching, same-patient, diagnostic, castra-
tion-sensitive prostate cancer (CSPC) biopsies, to determine
the extent of PSMA heterogeneity and how this may impact
the clinical utility of PSMA-theranostic strategies. Further-
more, given that intratumour heterogeneity can be signifi-
cantly increased by genomic instability [19], we have also
pursued next-generation sequencing (NGS) studies to
determine whether deleterious DNA damage repair (DDR)
aberrations, which are a well-described contributor to
genomic instability [20,21], are associated with PSMA
protein expression and whether DDR biomarkers can have
utility for guiding PSMA-directed therapies.
2. Patients and methods
2.1. Patients and tissue samples
All patients had mCRPC treated at the Institute of Cancer Research and
Royal Marsden Hospital (ICR/RMH), provided written informed consent,
and enrolled into institutional protocols approved by the RMH ethics
review committee (reference no. 04/Q0801/60). Patient clinical data
were retrospectively collected from the Royal Marsden NHS Foundation
Trust electronic patient record system.
2.1.1. ICR/RMH test cohort
Sixty patients were identified as having sufficient formalin-fixed,
paraffin-embedded (FFPE) mCRPC biopsies available for assessment, of
whom 38 also had matched, same-patient, diagnostic CSPC tissue
samples. All tissue blocks were freshly sectioned and considered for IHC
analyses only if adequate material was present (50 tumour cells). All
CSPC biopsies demonstrated adenocarcinoma.
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An independent cohortwith knownDDRaberrations (BRCA2homozygous
deletion,n = 10;ATM loss by IHC,n = 10;CDK12mutation,n = 6;mismatch
repair,n = 9), asdeterminedbyNGS, andwith sufficient FFPEmCRPCtissue
for IHC was compiled to validate the findings of the ICR/RMH test cohort.
2.1.3. International Stand Up To Cancer/Prostate Cancer Foundation
validation cohort
A total of 163 mCRPC transcriptomes generated by the International
Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF) Prostate
Cancer Dream Team were downloaded and reanalysed [22].
2.2. Antibody validation
AntibodyspecificitywasdeterminedbyWesternblot comparingdetection
of PSMA protein expression in LnCaP whole cell lysates cultured with
either nontargeting control siRNA or ON-TARGETplus pooled PSMA siRNA
(Dharmacon; GE Healthcare: Chicago, Illinois, United States).
2.3. Immunohistochemisty
PSMA IHC was performed using a mouse anti-PSMA antibody (M3620;
monoclonal [clone 3E6]; DAKO; Agilent Technologies: Santa Clara,
California, United States). Antigen retrieval was achieved by microwav-
ing slides in antigen retrieval buffer (Tris/EDTA buffer pH 8.1 diluted
1:10) for 18 min at 800 W prior to incubation with anti-PSMA antibody
(1:100 dilution) for 1 h at room temperature. The reactionwas visualised
using the EnVision system (K4061; DAKO). Antibody specificity was
confirmed in LnCaP (positive control) and PC3 (negative control)
xenograft models (Fig. 1A). Membranous PSMA quantification for each
sample was determined by a pathologist blinded to clinical and
molecular data using modified H-scores ([{% of weak staining}  1]
+ [{% of moderate staining}  2] + [{% of strong staining}  3]), to
determine the overall percentage of mPSMA positivity across the entire
stained tumour sample, yielding a range from 0 to 300 [23].
2.4. Determination of deleterious DNA damage repair
aberrations
Targeted NGSwas available for 56 patients within the ICR/RMH test cohort
andperformedusingDNAextracted fromtumourbiopsyandgermlineDNA
samples according to a previously published protocol [24,25]. Libraries
were constructed from40 ngofDNAusinga customisedGeneReadDNAseq
Mix-n-Match v2 panel (Qiagen: Hilden, Germany) and sequenced on the
MiSeq Sequencer (Illumina: San Diego, California, United States) at amean
depth of 874. Sequencing resultswere used to classify patientswithin the
study cohort as being either positive or negative for deleterious genomic
aberrations in DNA-repair genes, as listed in Supplementary Table 1 [24].
2.5. Gene expression and activity scores
Paired-end transcriptome sequencing reads were aligned to the human
reference genome (GRCh37/hg19) using Tophat2 (v2.0.7). Gene expres-
sion, Fragments Per Kilobase of transcript per Million mapped reads
(FPKM), was calculated using Cufflinks [26]. Double-strand break repair
scorewas calculated through cumulativemeasurement of 19 genes in the
homologous recombination repair pathway from the Molecular Signa-
tures Database (M11429).
2.6. Statistical analysis
H-scores were reported as median values and interquartile ranges.
Comparisons of mPSMA expression between CSPC and mCRPC tissuesamples, and correlations with NGS data were determined using the
Wilcoxon matched-pair signed rank test. Overall survival (OS) was
defined as time from diagnostic biopsy to the date of death. Median OS
was estimated using the Kaplan-Meier method, with hazard ratios
determined by Cox regression. Sample heterogeneity was quantified
using Shannon's diversity index (SDI) [27]. All analyses were conducted
using Stata v13.1; graphs were generated using GraphPad Prism v7.
3. Results
3.1. Antibody validation
To emulate PSMA-targeted diagnostics and theranostics
currently under clinical evaluation, anti-PSMA subclone
3E6, which targets an extracellular epitope of PSMA, was
chosen over the 7E11 subclone, which recognises the
intracellular portion of PSMA. Antibody specificity was
validated by Western blot demonstrating a reduction in
detectable PSMA protein expression following treatment
with PSMA-specific siRNA compared with nontargeting
control siRNA (Fig. 1B and Supplementary Fig. 2).3.2. Expression of mPSMA protein at diagnosis of PC is
heterogeneous and associated with a worse overall survival
Expression levels of mPSMA protein were evaluated in
38 CSPC PC biopsies obtained at diagnosis (median H-score
[interquartile range]: 17.5 [0.0–60.0]). Interestingly,16 (42%;
95% confidence interval [CI; 28–58%]) patient samples had
no detectable expression of mPSMA (H-score <10).
Furthermore, amongst the remaining biopsies that
expressed PSMA, there was not only apparent interpatient
heterogeneity, but also marked intrapatient heterogeneity
in expression, with all evaluated tissue samples exhibiting
areas without detectable PSMA (Fig. 1C). To quantify this
intratumour heterogeneity, each tumour biopsy was
assigned an SDI score; this revealed that not only did all
biopsies with detectable mPSMA exhibit heterogeneous
expression, but also that the degree of intrapatient
heterogeneity increased in parallel with mPSMA H-score.
To determine the clinical significance of mPSMA at PC
diagnosis, the association of mPSMA expression with
clinical characteristics and OS was determined. Higher
levels of mPSMA expression were associated with a higher
Gleason grade (p = 0.04; Supplementary Table 2) and a
worse overall survival (hazard ratio [95% CI]: H-score
<17.5 = 1.00 vs H-score 17.5 = 2.97 [1.38–6.43]; p = 0.006)
when dichotomised by the median H-score (Fig. 1H). Taken
together, these data indicate that in addition to a large
proportion of patients exhibiting no detectable PSMA
expression in their tumour biopsies at diagnosis of PC,
when mPSMA is present, its expression is inherently
heterogeneous. Furthermore, although the patient cohort
presented here is relatively limited in size, making
inferences on the impact of PSMA expression on survival
more challenging, our results suggest that mPSMA expres-
sion at PC diagnosis is associated with a poor prognosis and
a more aggressive histological phenotype, meriting further
evaluation in larger prospective datasets.
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Fig. 1 – Membranous PSMA (mPSMA) protein expression at the time of prostate cancer (PC) diagnosis is heterogeneous and is associated with a worse
overall survival. (A) Immunohistochemical (IHC) antibody validation performed using PC3 cell mouse xenograft, which does not express PSMA protein,
and PSMA-expressing LnCaP cell mouse xenograft, demonstrating positive brown membranous and cytoplasmic staining. (B) Antibody signal specificity
confirmed by detection of a single band in LnCaP whole-cell lysates by Western blot, with downregulation following treatment with pooled PSMA
siRNA compared with nontargeting control siRNA. (C) Graphical representation of mPSMA protein expression in tissue samples obtained from patients
with castration-sensitive prostate cancer (CSPC) obtained at diagnosis of PC. Expression of mPSMA protein quantified by H-score and presented in
order of increasing H-score. Degree of heterogeneity in mPSMA protein expression observed within samples measured by Shannon's diversity index
(SDI) and depicted as heat map ranging from low heterogeneity (white) to high heterogeneity (orange). Of the 38 CSPC tissue samples analysed
(median H-score [interquartile range]: 17.5 [0.0–60.0]), 16 (42%; 95% CI [28–58%]) were found to be negative for mPSMA protein expression (H-score
<10). Among the 26 remaining samples, as mPSMA protein expression increased, so too did the degree of intrasample heterogeneity, with all CSPC
biopsies that expressed mPSMA (PSMA 1+, PSMA 2+, or PSMA 3+) also exhibiting areas of tumour with no detectable PSMA expression (PSMA 0). (D–G)
Examples of microscopic appearance of PSMA IHC. All scale bars are set to 100mm. (D) Prostatectomy demonstrating prostatic adenocarcinoma with
no detectable PSMA expression. (E) Prostate biopsy containing prostate cancer cells with strong brown positive membranous and cytoplasmic staining
for PSMA. (F) Prostatectomy and (G) prostate biopsy showing heterogeneity in PSMA expression with areas of strong PSMA expression (PSMA 2+ and
PSMA 3+) interspersed amongst tumour cells with no detectable PSMA protein expression (PSMA 0). (H) High PSMA protein expression (H-
score>median) at the time of prostate cancer diagnosis associated with significantly shorter median OS. Bx = biopsy; CI = confidence interval;
HR = hazard ratio; OS = overall survival; PSMA = prostate-specific membrane antigen.
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Fig. 2 – Expression of mPSMA protein is upregulated in mCRPC, but demonstrates marked intra- and interpatient heterogeneity. (A) Graphic
representation of mPSMA protein expression in mCRPC tissue samples. Expression of mPSMA protein quantified by H-score and presented in order of
increasing H-score. Intrasample heterogeneity of mPSMA protein expression quantified by SDI and depicted as a heat map ranging from low
heterogeneity (white) to high heterogeneity (orange). Tumours with histopathological evidence of neuroendocrine differentiation, confirmed by
detectable synaptophysin and/or chromogranin A by IHC, are highlighted by green boxes around patient identifiers. Overall mPSMA expression levels
were higher in mCRPC (55.0 [2.8–117.5]; n = 60); however, as seen in CSPC tissue biopsies, 27% (n = 16; 95% CI [17–39%]) of mCRPC patient biopsies had
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demonstrates marked intra- and interpatient heterogeneity
Median mCRPC mPSMA H-score was 55.0 ([2.8–117.5];
n = 60). Importantly, 16 (27% [17–39%]) mCRPC biopsies had
no detectable expression of mPSMA, with only one patient
(patient 11) having evidence of neuroendocrine differenti-
ation. Interestingly, a comparison with matched, same-
patient CSPC tissue samples revealed that half of these
samples with no mPSMA protein expression were also
negative for mPSMA expression at PC diagnosis. In keeping
with our findings in CSPC biopsies, 37 of the 44 (84% [71–
92%]) mCRPC biopsies expressing mPSMA demonstrated
marked heterogeneity in expression (Fig. 2A), with SDI
scores similarly increasing in line with the H-score. While
the degree of heterogeneity in mPSMA expression varied
between patient samples, common patterns of mPSMA
expression were identified. These included the following:
(1) PSMA-positive and PSMA-negative cells interspersed
within a single area of prostate adenocarcinoma (Fig. 2C);
(2) clusters of adenocarcinoma cells with strong PSMA
expression intertwined within regions of PSMA-null tu-
mour cells (Fig. 2D); and (3) discrete nodular PSMA
expression, with regions of PSMA-negative tumour cells
segregated away from regions of PSMA expressing cells, a
number of which were >2 mm apart, which is the maximal
tissue penetrance of the beta particle emitter 177Lu (Fig. 2F).
Furthermore, heterogeneous mPSMA expression between
metastases from the same patient was also observed
(Fig. 2G). To determine whether mPSMA expression levels
were dependent on the type of tissue biopsied, mPSMA
expression was correlated with mCRPC biopsy site. No
difference was observed between samples obtained from
bone (n = 25) and lymphoid tissue (n = 22); however,
interestingly, a significant reduction in mPSMA expression
was observed in liver metastases (n = 8), with none of these
biopsies demonstrating overt neuroendocrine differentia-
tion. Taken together, these data indicate that while mPSMA
increases in mCRPC, a significant proportion of patients
exhibit no detectable PSMA. When present, however,
mPSMA expression in mCRPC exhibits marked intra- andno detectable expression of mPSMA (H-score <10). Interestingly, eight (50% [28
the diagnosis of PC. Expression of mPSMA in mCRPC also demonstrated marke
mCRPC biopsies that expressed mPSMA (n = 44; PSMA 1+, PSMA 2+,or PSMA 3+
(PSMA 0), and only 10 (23% [13–37%) mPSMA-positive mCRPC samples not con
(PSMA 0). (B–E) Examples of microscopic appearance of PSMA IHC. All scale ba
adenocarcinoma with no detectable PSMA expression. (C) Soft tissue metastasi
expression (brown) interspersed and juxtaposed alongside tumour cells with n
exhibiting strongly positive PSMA expressing cells (PSMA 2+ and PSMA 3+) inte
Lymph node biopsy with strong positive membranous and cytoplasmic stainin
biopsy highlighting the clinical significance of PSMA intratumour heterogenei
(arrow) segregated away from the region of PSMA-expressing cells (brown) an
Bone and lymph node mCRPC biopsies from the same patient demonstrating s
mPSMA significantly higher (p = 0.005) in mCRPC biopsies (55.0 [2.8–117.5]; n =
with matched, same-patient CSPC tissue samples (n = 38), however, revealed po
samples. (J) Expression of mPSMA increases in most patients on progression to
(change in H-score <5), while nine (24% [13–39%]) had less mPSMA protein ex
with no change in mPSMA expression were negative for mPSMA expression at
mCRPC. (K) Comparison of mPSMA expression levels relative to the type of tiss
from bone (n = 25) and lymphoid tissue (n = 22); however, significantly lower m
demonstrating overt evidence of neuroendocrine differentiation. BM = bone m
cancer; HR = hazard ratio; LN = lymph node; mCRPC = metastatic castration-res
PC = prostate cancer; PSMA = prostate-specific membrane antigen; SDI = Shannointerpatient heterogeneity, resulting in clinically significant
distances between areas of PSMA-expressing and PSMA-
null cells, potentially impacting the clinical utility of PSMA
theranostics. Furthermore, while absence of mPSMA
expression at diagnosis was associated with a lack of
mPSMA mCRPC expression, there was poor concordance
between mPSMA expression at diagnosis of PC and at
castration-resistant disease.
3.4. Expression of mPSMA protein in mCRPC is associated with
deleterious DNA repair aberrations
In light of the observed marked heterogeneity of mPSMA
expression, and given that intratumour heterogeneity can
be significantly increased by genomic instability [19],
targeted NGS data were analysed to identify potential
associations between mPSMA expression and deleterious
DDR aberrations (Fig. 3A). Interestingly, mCRPC patients
with deleterious DDR aberrations were found to have
significantly higher (p = 0.016) mPSMA expression than
those without these aberrations (DDR 87.5 [25.0–247.5] vs
no DDR 20 [0.3–98.8]; difference in medians 60 [5.0–95.0];
Fig. 3B). Furthermore, when comparing the change in
mPSMA protein expression between matched, same-pa-
tient CSPC and mCRPC tissue samples, we observed that
while mPSMA expression increased significantly in mCRPC
patients with detectable DDR aberrations (p = 0.02), this
was not the case for patients without detectable DDR gene
mutations (p = 0.19) (Coef = 35; 95% CI: 2–68; p = 0.04;
Fig. 3C). Interestingly, in keeping with these findings,
although not statistically significant, amongst the
37 patients within our patient cohort who received
treatment with a PARP inhibitor, nine of the 11 (82%)
patients who responded to therapy had a mPSMA H-score
above the median (55.0 [2.8–117.5]). To validate the
association between mPSMA expression and deleterious
DDR aberrations, mCRPC mPSMA expression levels were
evaluated in an independent PC cohort with known DDR
aberrations. Tumours with deleterious DDR aberrations
were found to have significantly higher mPSMA expression
levels than unselected mCRPC biopsies (BRCA2 300 [165––72%]) of these patients were also negative for mPSMA expression at
d intra- and intertumour heterogeneity, with 84% ([71–92%]; n = 37) of
) also exhibiting areas of tumour with no detectable PSMA expression
taining regions of tumour cells with no mPSMA protein expression
rs are set to 100mm. (B) Bone marrow trephine demonstrating prostatic
s showing adenocarcinoma cells with moderate (PSMA 2+) PSMA
o detectable PSMA expression (PSMA 0). (D) Lymph node biopsy
rtwined within a region of PSMA-negative (PSMA 0) tumour cells. (E)
g for PSMA (PSMA 3+) with no PSMA negative cells. (F) Lymph node
ty. Discrete nodule of tumour cells with no PSMA protein expression
d located beyond the maximal tissue penetrance of 177Lu (red circle). (G)
ignificant heterogeneity between metastases. (H) Expression levels of
60) compared with CSPC biopsies (17.5 [0.0–60.0]; n = 38). (I) Comparison
or concordance in mPSMA expression levels between CSPC and mCRPC
mCRPC; however, nine patients had no change in expression levels
pression at mCRPC. Interestingly, eight (89% [57–99%]) of the patients
the diagnosis of PC (H-score <10), and remained so on progression to
ue biopsied. No difference was observed between samples obtained
PSMA expression was seen in liver metastases (n = 8), none of which
arrow; CI = confidence interval; CSPC = castration-sensitive prostate
istant PC; mPSMA = membranous PSMA; NS = not significant;
n's diversity index; ST = soft tissue.
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Fig. 3 – Expression of mPSMA protein in mCRPC is significantly higher in patients with deleterious DNA repair genomic aberrations. (A) Bar graph
representing mPSMA protein expression in mCRPC patient biopsies (n = 60) presented in order of increasing H-score. Median H-score (55.0 [2.8–117.5])
demarcated by blue dashed line. Deleterious DNA damage repair (DDR) aberrations, as detected by next-generation sequencing (NGS) of patient tissue
samples, are indicated by red boxes with affected gene labelled below; PARP inhibitor sensitising aberrations are depicted as dark red boxes and
genomic variants of currently unknown significance as light red boxes. Green boxes depict patients with documented response to PARP inhibitor
therapy. Grey boxes depict patients for whom mCRPC NGS data were not available (n = 4). (B) Patients with deleterious DDR aberrations in genes
involved in the DNA repair pathway have significantly higher (p = 0.016; Wilcoxon rank-sum analysis) levels of mPSMA expression than those without
these (DDR 87.5 [25.0–247.5] vs no DDR 20 [0.3–98.8]; difference in medians 60 [5.0–95.0]). (C) Expression of mPSMA increases significantly (p = 0.02) in
mCRPC, compared with CSPC, in patients with detected deleterious DDR aberrations (median CSPC H-score = 17.5 [0.3–47.5] vs median mCRPC H-
score = 80 [25–237.5]), unlike patients without DDR aberrations (median CSPC H-score = 15 [0–62.5] vs median mCRPC H-score = 20 [0–96.3]; p = 0.19)
(Coef = 35; 95% CI: 2–68; p = 0.04). (D) Association between mPSMA expression and deleterious DDR aberrations was validated in an independent cohort
with known DDR aberrations. Tumours with DDR aberrations had significantly higher mPSMA expression (BRCA2 300 [165–300], difference in medians
195.0 [100.0–270.0], p = < 0.001; ATM 212.5 [136.3–300], difference in medians 140.0 [55.0–200.0], p = 0.005; CDK12 137.5 [41.3–272.5], difference in
medians 45 [20.0 to 175.0], p = 0.1; MMR 110.0 [72.5–240.0], difference in medians 60 [5.0–110.0], p = 0.032) than unselected mCRPC biopsies, as shown
by the dashed line (55.0 [2.75–117.5]). All p values were calculated using Mann-Whitney test. * p < 0.05, ** p < 0.01, *** p < 0.001. CI = confidence
interval; CSPC = castration-sensitive prostate cancer; mCRPC = metastatic castration-resistant prostate cancer; mPSMA =membranous prostate-specific
membrane antigen.
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ATM 212.5 [136.3–300], difference in medians 140.0 [55.0–
200.0], p = 0.005; CDK12 137.5 [41.3–272.5], difference in
medians 45 [20.0 to 175.0], p = 0.1; MMR 110.0 [72.5–
240.0], difference in medians 60 [5.0–110.0], p = 0.03;
Fig. 3D). Taken together, these data suggest that deleterious
DDR aberrations are associated with significantly higher
mPSMA expression levels in mCRPC.
3.5. Metastatic CRPC transcriptome analyses: PSMA, double-
strand break repair, BRCA2, and epithelial-mesenchymal transition
To further explore the association between PSMA expression
and DNA repair, analysis of RNA-sequencing data obtained
from 163 mCRPC transcriptomes was performed (SU2C/PCF
validation cohort). This demonstrated an inverse correlation
between PSMA mRNA expression, and both BRCA2 mRNA
expression (p < 0.001; Fig. 4A) and double-strand break
repair (p < 0.001;Fig. 4C),which, taken together, suggest that
high PSMA expression in mCRPC is associated with BRCA2loss and a reduction in homology-dependent DNA repair.
Furthermore, since RB1 can be codeleted with BRCA2, with
emerging endocrine resistance and luminal to basal transi-
tionwith associated hyperexpression of SOX2, we correlated
SOX2 expression with PSMA expression [28,29]. PSMA
expression correlated negatively and robustly with SOX2
(p < 0.001; Fig. 4D), SNAI1 (p< 0.001; Fig. 4E), SNAI2
(p = 0.039; Fig. 4F), NCAM1 (p< 0.001; Fig. 4G), and EON2
(p < 0.001; Fig. 4H) expression levels, suggesting down-
regulation of PSMA expression with luminal to basal
transition and the neuroendocrine-like phenotype.4. Discussion
The protein PSMA, which is arguably critical to folate and
glutamate PC cell uptake necessary for maintaining geno-
mic stability, has become a key target for PC theranostics [8–
11]. Early-phase trials of PSMA-targeting theranostics,
including immunoconjugates, radioimmunoconjugates car-
[(Fig._4)TD$FIG]
Fig. 4 – PSMA mRNA expression is inversely correlated with BRCA2 mRNA expression and double-strand break repair. Analysis of RNA-sequencing data
obtained from 163 mCRPC transcriptomes demonstrating an inverse correlation between PSMA mRNA expression, and (A) BRCA2 mRNA expression
(p < 0.001) and (B) ATM mRNA expression (p = 0.059), associating PSMA expression with BRCA2 loss. (C) An inverse correlation was observed between
PSMA mRNA expression and an mRNA signature of double-strand break repair activity (p < 0.001) calculated through cumulative measurement of
19 genes involved in homologous recombination DNA repair, as determined from the Molecular Signatures Database (M11429), indicating that as PSMA
mRNA expression increases, DDR activity decreases. (D) PSMA expression was also found to be inversely correlated with SOX2 mRNA expression
(p < 0.001), as well as with (E) SNAI1 (p < 0.001), (F) SNAI2 (p = 0.039), (G) NCAM1 (p < 0.001), and (H) ENO2 (p < 0.001) expression levels, suggesting a
downregulation of PSMA expression with luminal to basal transition and the neuroendocrine-like phenotype. DDR = defective DNA repair;
FPKM = Fragments Per Kilobase of transcript per Million mapped reads; mCRPC = metastatic castration-resistant prostate cancer; PSMA = prostate-
specific membrane antigen.
E U RO P E AN URO L OGY 76 ( 2 019 ) 4 6 9 – 47 8476rying alpha- and beta-emitting particles, and bispecific
antibodies targeting CD3 and PSMA, have reported anti-
tumour activity against mCRPC. These trials have often
recruited patients with positive PSMA-ligand uptake on PET
[10,11]; however, this patient selection is not always being
pursued so as to minimise cost. De novo and acquired
resistance to these agents has also been reported, and is
likely to be at least in part related to the absence or loss of
PSMA expression, although the mechanisms for these have
not been fully elucidated to date. A better understanding of
inter- and intratumour heterogeneity in PSMA expression is
now key to successful development of these agents.We now
present the first robust evidence that PC PSMA expression isstrongly associated with DNA repair defective tumours,
perhaps explaining why therapeutics that generate double-
strand DNA breaks, such as radioimmunoconjugates, have
had antitumour activity against PC. We propose that future
trials with these agents should consider targeting DDR PC.
These data are supported by a recent case report of an
exceptional response to 177Lu in a patient harbouring BRCA2
loss [30].
While our analyses presented here focus on mPSMA,
given that we believe that this represents a more clinically
relevant measure of PSMA expression in PC, we acknowl-
edge that differentiation between membranous and cyto-
plasmic PSMA expression, particularly in cases where
EU RO P E AN U RO L OGY 76 ( 2 019 ) 4 6 9 – 47 8 477cytoplasmic PSMA expression is high, may be a limitation of
our work. Despite this, our data herein indicate that the
inherent intratumour heterogeneity of PSMA expression in
PC represents a significant potential contributor to resistance
to these therapies. Furthermore, while our conclusions are
limited by the retrospective nature of our study and the
relatively small size of our patient cohorts, we envision that
trials that donotmandate evidence of PSMAexpressionprior
to enrolment will inevitably observe lower rates of response.
Moreover, our data indicating that livermetastases inmCRPC
have very low PSMA expression also raise concern that
patients suffering from these may not benefit from these
therapies, with these tumours perhaps being more likely to
have an emerging basal phenotype [31–33]. Further studies
are now needed to determine whether this will be a
commoner site of resistance to PSMA-targeting therapies.
The association between PSMA and deleterious DDR
aberrations also raises many interesting questions for future
study. Importantly, we do not propose that deleterious DDR
aberrations alone cause increased expression of PSMA.
Rather, we hypothesise that the biological consequences
for tumour cells of having deleterious aberrations in DDR
genes potentially promote the overexpression of PSMA.
Deleterious DDR aberrations are associated with replication
stress, placing increased demand for metabolic precursors
such as folate and glutamate, which are crucial to DNA
synthesis and repair. As such, given the enzymatic capability
of PSMA to yield glutamate and folate monoglutamate from
polyglutamated folates [2], and its reported role as a folate
transporter [1], one possible explanation to account for this
association is that PSMA overexpression in cells with
deleterious DDR aberrations represents an adaptive cellular
response. In this setting, PSMA overexpressionmay be being
drivenby the increased requirement of these cells for cellular
metabolites such as folate and glutamate. Alternatively,
PSMA has also been reported to promote PI3K-Akt signalling
[3,34]. Thishasbeendemonstrated to suppressDNArepair by
homologous recombination, which is defective in cells with
deleterious DDR aberrations such as BRCA2 loss, and also to
enhance nonhomologous end joining [35]. This again hints
towards PSMA serving as a survival mechanism for PC cells
with DDR. Most likely, however, themechanisms underlying
the expression of PSMA are multifactorial, involving a
complex interaction between numerous cellular processes.
In spite of these uncertainties, it is clear that a deeper
understanding of the biology of PSMA in PC is now needed,
firstly, to account for this association, but also to elucidate
pharmacological strategies that can manipulate PSMA
expression, for example, perhaps through generating PC
genomic instability or replication stress. Such strategiesmay
informon thedevelopment of optimaldrug combinations for
PSMA-targeting therapeutics.5. Conclusions
Expression ofmPSMA is upregulated inmany but not all PCs,
and exhibits marked intra- and interpatient heterogeneity.
DDRgeneaberrationsareassociatedwithsignificantlyhighermPSMA expression levels and merit further evaluation as
predictive biomarkers of response for PSMA-targeted thera-
pies in larger, prospective clinical trials.
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